Myocardial infarction and other major vascular events during chemotherapy for testicular cancer

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1607-1611

  Dieckmann, K P ^a   Gerl, A ^b   Witt, J ^a   Hartmann, J T ^c  

^a ALBERTINEN KRANKENHAUS   (Germany)

^b Onkologische Schwerpunktpraxis   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Cisplatin; Myocardial infarction; Testicular cancer; Thromboembolism; Vascular complication

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; GERM CELL TUMOR; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; TESTIS CANCER; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; QUESTIONNAIRES; TESTICULAR NEOPLASMS; VASCULAR DISEASES;

EID: 77955251029     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp597     Document Type: Article

References (27)

1. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 2008; 53: 497-513.
2. Fizazi K, Chen I, Logothetis CJ. Germ-cell tumor survivors: the price for cure. Ann Oncol 2002; 13: 187-189.
3. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 866-869.
4. Strumberg D, Brugge S, Korn MW et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-236.
5. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-1523.
6. van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-475.
7. Oldenburg J, Fossa SD. [Long-term toxicity after therapy for testicular cancer with special focus on sexual disorders]. Urologe A 2009; 48: 372-376.
8. Wethal T, Kjekshus J, Roislien J et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007; 1: 8-16.
9. Vaughn DJ, Palmer SC, Carver JR et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112: 1949-1953.
10. Nuver J, Smit AJ, van der Meer J et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23: 9130-9137.
11. Piketty AC, Flechon A, Laplanche A et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005; 93: 909-914.
12. Dieckmann KP. [Pre- and paraclinical cooperative trials on testicular cancer: background and overview of current trials.] [Article in German]. Urologe A 2007; 46: 1180-1184.
13. Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs 1994; 5: 607-614.
14. Ozben B, Kurt R, Oflaz H et al. Acute anterior myocardial infarction after chemotherapy for testicular seminoma in a young patient. Clin Appl Thromb Hemost 2007; 13: 439-442.
15. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs 2008; 19: 927-929.
16. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478-496.
17. Bastian PJ, Skowasch D, Bauriedel G et al. Primary extragonadal germ cell tumor of the prostate in a young man. Int J Urol 2004; 11: 671-673.
18. Weijl NI, Rutten MF, Zwinderman AH et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000; 18: 2169-2178.
19. Gerl A. Does chemotherapy for testicular cancer increase cardiovascular risk? In Jones WG, Appleyard I, Harnden P, Joffe JK (eds), Germ Cell Tumours IV: The Proceedings of the Fourth Germ Cell Tumour Conference, Leeds November 1997. London: John Libbey & Company 1998; 397-400.
20. Brouha ME, Bloemendal HJ, Kappelle LJ, Winter JB. [Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy.] [Article in Dutch]. Ned Tijdschr Geneeskd 2003; 147: 457-460.
21. Dietrich J, Marienhagen J, Schalke B et al. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 2004; 38: 242-246.
22. Karagoz B, Bilgi O, Akyol I et al. Cerebrovascular accident after chemotherapy for testicular cancer. Mil Med 2009; 174: 320-321.
23. Icli F, Karaoguz H, Dincol D et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72: 587-593.
24. Vos AH, Splinter TA, van der Heul C. Arterial occlusive events during chemotherapy for germ cell cancer. Neth J Med 2001; 59: 295-299.
25. Le Ho H, Vauleon E, Boucher E et al. Acute ischemia of the lower limb during chemotherapy for testicular cancer: a report of two cases. Acta Oncol 2009; 48: 940-942.
26. Starling N, Rao S, Cunningham D et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-3793.
27. Lü C-F, Yu H-J, Hou J-X, Zhou J. Increased procoagulant activity of red blood cells in the presence of cisplatin. Chin Med J (Engl) 2008; 121: 1775-1780.